18F-FDG is a robust probe for in vivo analysis of glycolysis, a hallmark of tumor development and an early biomarker for therapeutic efficacy.
PET Imaging With Applications In Mind
PET is an essential imaging tool for preclinical translational research, and the G4 and G8 systems were built with PET imaging applications in mind. PET allows the visualization and quantification of biological events across a variety of disease models. Whether your research focuses on oncology, cardiovascular disease or drug discovery, the G-Platform will bring translatable data to your current research workflow.
Radiolabeling of potential therapeutics allows for real-time assessment of delivery to the target as well as in vivo biodistribution, accelerating drug discovery.
Antibody imaging (with 89Zr, 124I, 64Cu) is a sensitive, non-invasive means for molecular characterization to guide diagnosis, prognosis, therapy selection, and monitoring treatment in cancer.
Courtesy of Richard Tavare, Wu lab, UCLA.
18F-Fallypride allows for non-invasive in vivo imaging of dopamine D2/3 receptors, in mice (left) and rats (right), providing invaluable mechanistic insights into neurodegenerative diseases.
When administered in vivo, 18F-NaF incorporates rapidly into the apatite crystals of bones, identifying regions of bone metabolism, often a hallmark of metastatic cancer or osteoporosis.
The increased PET sensitivity on the G4 and G8 allow for detection of trace amounts of probe, facilitating in vivo testing of novel imaging probes even when radiochemical yields are low.
For Research Use Only. Not for Use in Diagnostic Procedures.